ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCRX vs BEAM // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

BioCryst Pharmaceuticals Inc. (NASDAQ) VS. Beam Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: BCRX 3 — BEAM 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCRX VS. BEAM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCRX BEAM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -32.10% +117.10 BCRX /roic <GO>
EV/EBITDA & P/E Valuation 6.1x — — TIE /valuation <GO>
Free Cash Flow Yield 15.96% -12.09% +28.05 BCRX /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -57.20% — TIE /net-margins <GO>
Revenue Growth (YoY) — 120.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 6.00 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 6/9 3/9 +3.00 BCRX /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 48.8 50.1 -1.30 BEAM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 7.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.11B $2.67B -$565.2M BEAM /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCRX REV BEAM REV BCRX GROSS % BEAM GROSS % BCRX FCF BEAM FCF
FY 2025 $954.8M $139.7M — — $347.4M -$360.0M
FY 2024 $7.1M $63.5M — — -$52.0M -$356.2M
FY 2023 $290.4M $377.7M — — -$95.1M -$149.2M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCRX // BETA —
BEAM // BETA —